Company
STRM.BIO
Expanding the Possibilities of in vivo Gene Therapy
Also known as STRM.BIO, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- STRM.BIO, Inc.
- strm.bio (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
STRM.BIO megakaryocyte-derived extracellular vesicles (STRM MVs) offer a fundamentally different approach for gene therapy delivery. STRM MVs harness cell-type specific biological attributes to target and deliver complex genetic cargoes preferentially to bone marrow.
Funding snapshot
- Total raised
- $10.1MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Seed extension, $8M2026-01-07
Funding rounds
- Seed extension
- $8M2026-01-07, Company stated
- Grant
- $2.1M2022-07-26, Company stated
Products
- Other
- STRM MVs
- Web
- STRM MVs
Loading relationship preview